Understanding the Consumer Journey with GLP-1 Medications
Omada Health has recently released findings from an insightful survey exploring the experiences of individuals using GLP-1 medications for weight loss. This research focused on the challenges faced throughout the user experience, revealing that a significant portion of users often discontinue their treatment prior to reaching their desired weight goals. With obesity levels on the rise, understanding the consumer journey is crucial for improving health outcomes.
Key Findings from the Survey
In a survey of 1,000 non-Omada members aged 21 to 75, it was discovered that 78% of participants discussed lifestyle changes with their healthcare providers when prescribed GLP-1 medications. An emotional component heavily influences this journey, as 82% of respondents reported that their weight affected their emotional health prior to taking these medications. Notably, 62% felt hopeful upon starting GLP-1 treatments.
Discontinuation Rates and Emotional Impact
While these medications can be effective, the survey revealed troubling statistics about discontinuation rates. Approximately 65% of users who stopped taking GLP-1 medications reported experiencing feelings of anxiety, stress, or depression. Alarmingly, more than three-quarters of these individuals regained some of the weight they worked hard to lose.
Barriers to Medication Persistence
The survey further highlighted various barriers affecting users' abilities to stay on their prescribed medications. Access to medications and financial concerns emerged as significant challenges. Key results included:
- 73% of respondents were first prescribed GLP-1s by their primary healthcare providers.
- Over 60% encountered challenges when refilling their prescriptions, resulting in medication skipping or brand switching.
- 35% cited out-of-pocket costs as a reason for discontinuation, while only 18% stopped once they achieved their weight loss goals.
- A striking 66% regained some weight after stopping the medication; only 11% continued to lose weight.
The Need for Comprehensive Support
According to Carolyn Bradner Jasik, M.D., Chief Medical Officer at Omada Health, the findings emphasize the importance of additional support beyond just prescribing medications. She stated, “This survey is critical to unpacking the complexity and ambiguity of the GLP-1 patient journey, while further emphasizing the need for support beyond prescribed weight loss medications.” This highlights the necessity for integrated behavioral change programs aimed at fostering enduring results.
Expanding Understanding Through Real-World Data
Omada’s additional study titled “GLP-1 Discontinuation: Real World Perspectives on a Complex Journey” affirmed that access challenges predominantly led to discontinuation among 75% of participants. Despite stopping the medications, 87% expressed a desire to continue their weight loss journey.
Context of GLP-1 Usage in American Health Trends
GLP-1 medications have garnered increasing attention as effective treatments for weight loss in the context of rising obesity rates among Americans, with recent data indicating that 42% of the U.S. population is affected by obesity. Omada’s research is part of their ANSWERS initiative, which investigates the impact of lifestyle programs on the overall success of weight loss treatments, both with and without GLP-1 usage.
Commitment to Continuous Improvement
Omada Health remains dedicated to enhancing its understanding of GLP-1 treatments by studying the influence of lifestyle interventions on user experiences at every stage of their journey. The ongoing evolution of chronic disease management through GLP-1s highlights the importance of adapting clinical research to better support individuals on these medications.
Learn More About Omada Health
Through extensive experience and implementation of scientifically validated behavior change protocols, Omada aims to transform the health outcomes of individuals grappling with various health issues, including obesity. The company partners with over 2,000 customers and has established itself as a pioneering virtual healthcare provider, continuously striving to make a difference in the lives of its members.
Frequently Asked Questions
What were the main findings of the Omada Health survey?
The survey revealed that a majority of GLP-1 users discontinue the medication before achieving their weight loss goals, facing challenges related to cost and access.
How do GLP-1s impact emotional health?
Many users reported that their weight affected their emotional well-being, highlighting the complex relationship between weight and mental health.
What percentage of users regained weight after discontinuing GLP-1?
Approximately 66% of users regained some of the weight they had lost after stopping the medication.
Why do individuals discontinue GLP-1 medications?
Common reasons include out-of-pocket costs and challenges with prescription refills, with many users switching brands or pharmacies.
What is Omada Health’s approach to weight management?
Omada combines behavioral support programs with medical treatments like GLP-1s to improve long-term health outcomes for individuals.
